Crispr Therapeut Stock Price, News & Analysis

CRISPR Therapeutics (Nasdaq: CRSP) has announced participation in three virtual investor conferences in June 2021. The events include the Jefferies Virtual Healthcare Conference on June 1 at 1:00 p.m. ET, the William Blair 41st Annual Growth Stock Conference on June 3 at 12:20 p.m. ET, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 3:00 p.m. ET. Live webcasts of these presentations will be accessible on the company's website, and recordings will be available for 14 days post-event.

Vertex Pharmaceuticals and CRISPR Therapeutics announced the acceptance of two abstracts for presentation at the EHA 2021 Virtual Congress. The studies focus on CTX001, a gene-editing therapy for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta-Thalassemia (TDT). Both abstracts detail safety and efficacy results from ongoing clinical trials, with data on patients showing promising follow-up outcomes. CTX001 aims to alleviate severe symptoms by increasing fetal hemoglobin levels, potentially reducing transfusion needs and sickle crises.

CRISPR Therapeutics and Nkarta have announced a strategic partnership to co-develop gene-edited cell therapies for cancer. The collaboration will focus on two chimeric antigen receptor (CAR) NK cell product candidates targeting CD70 and a novel NK+T product. Nkarta obtains a license for CRISPR gene editing technology for its NK cell therapies. Both companies will equally share R&D costs and profits, with a three-year exclusivity period for allogeneic, gene-edited NK cells. This partnership aims to accelerate the development of new cancer therapies, leveraging their expertise.

CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two virtual investor conferences. The Truist Securities Life Sciences Summit is set for May 5, 2021, at 11:20 a.m. ET. Following that, the 2021 Bank of America Healthcare Conference will occur on May 12, 2021, at 2:00 p.m. ET. Live webcasts will be available on the company's website, with replays archived for 14 days post-presentation. CRISPR Therapeutics focuses on gene-based medicines, leveraging its proprietary CRISPR/Cas9 technology across various disease areas.

CRISPR Therapeutics (Nasdaq: CRSP) announced a Trials in Progress poster presentation for its ongoing Phase 1 CARBON trial at the American Society of Clinical Oncology Annual Meeting. The presentation will cover the safety and efficacy of CTX110™, an allogeneic CAR-T investigational therapy targeting CD19, for treating relapsed or refractory B-cell malignancies. The virtual event will occur from June 4 to 8, 2021, with the poster session scheduled for 9:00 AM ET on June 4.

CRISPR Therapeutics (Nasdaq: CRSP) announced it received Priority Medicines designation from the European Medicines Agency for CTX001™, a gene-edited therapy for transfusion-dependent beta thalassemia (TDT). Over 30 patients have been dosed in ongoing trials, with enrollment completion expected in 2021. The company's financial results for Q1 2021 showed a net loss of $113.2 million, an increase from $69.7 million the previous year, and R&D expenses rose to $90.6 million. CRISPR also amended its agreement with Vertex for CTX001, sharing costs and profits 40/60.

BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 – Vertex Pharmaceuticals and CRISPR Therapeutics announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, a CRISPR/Cas9 gene-edited therapy for transfusion-dependent beta thalassemia (TDT). This designation aims to expedite the development and evaluation of innovative therapies.

CTX001 has also received multiple FDA designations and is currently being evaluated in ongoing clinical trials for TDT and severe sickle cell disease (SCD).

Vertex Pharmaceuticals and CRISPR Therapeutics have revised their collaboration agreement for CTX001, a CRISPR/Cas9-based gene editing therapy aimed at treating sickle cell disease and beta-thalassemia. Vertex will lead the development, manufacturing, and commercialization of CTX001, responsible for 60% of program costs and profits. CRISPR will receive a $900 million upfront payment and up to $200 million upon regulatory approval. Vertex sees significant commercial potential in CTX001, having dosed over 30 patients with encouraging clinical results.

CRISPR Therapeutics (Nasdaq: CRSP) announced promising preclinical data from its allogeneic CAR-T program at the AACR Annual Meeting 2021. The study showcased that CAR-T cells with CD70 knockout displayed enhanced potency and persistence compared to conventional CAR-T cells. The research explored the effects of CRISPR/Cas9 gene editing on various checkpoint genes, revealing CD70's superior efficacy. The ongoing clinical trials of CTX130, targeting CD70-expressing tumors, expect to report top-line data in 2021, marking a significant step in cancer treatment innovation.